Almost every discussion of fisetin dosing starts from the label. A bottle says 500 mg, a protocol says 1,000 mg, and the conversation moves on to how many capsules to take. What that framing quietly assumes is that the number on the bottle has some predictable relationship to the amount of fisetin circulating in your blood. For fisetin, that assumption does not hold, and until recently nobody had measured how badly it fails in humans.
In 2022 the first human pharmacokinetic study of fisetin was published [1]. It is a small study, and it was designed to test a specific commercial formulation rather than to settle dosing for everyone. But the numbers it produced are the most useful human data on this page’s subject, because they measure the one thing labels cannot tell you: what actually gets in.
Key Takeaways
- The first human pharmacokinetic study of fisetin was published in 2022 and used fifteen healthy volunteers in a crossover design.
- A formulation delivering 192 mg of fisetin produced 26.9 times the twelve-hour plasma exposure of 1,000 mg of unformulated fisetin.
- Peak plasma concentration was 238.2 ng/mL versus 9.97 ng/mL, more than a twenty-three-fold difference.
- Label milligrams are a poor guide to how much fisetin reaches the blood, which makes price-per-milligram comparisons unreliable.
- No human study has established what plasma level of fisetin, if any, produces a clinical benefit.
Important: This article describes pharmacokinetic measurements, not clinical outcomes. Nothing here shows that fisetin treats or prevents any condition, and no plasma concentration of fisetin has been linked to a health benefit in humans. Fisetin can inhibit drug-metabolising enzymes and may interact with prescription medicines. Speak to a doctor or pharmacist before taking fisetin, particularly if you take anticoagulants, statins, immunosuppressants or blood pressure medication.
What the study did
The trial was a single-dose, randomised, double-blinded, comparative crossover study in fifteen healthy volunteers [1]. Each participant received both treatments, separated by a ten-day washout, so each person served as their own comparison. That design matters for a compound with high between-person variability, because it removes the differences between individuals from the comparison.
The two treatments were 1,000 mg of unformulated fisetin, and 1,000 mg of a formulated product called FF-20, which delivers 192 mg of fisetin. FF-20 is made by encapsulating fisetin micelles into a fenugreek galactomannan hydrogel scaffold. Blood was drawn at 0.5, 1, 2, 3, 5, 8 and 12 hours after each dose, and assayed for both fisetin and geraldol, an active metabolite.
Read the two arms carefully, because the comparison is not what it first looks like. It is not 1,000 mg against 1,000 mg of the same substance. It is 1,000 mg of raw fisetin against a product containing 192 mg of fisetin. The formulated arm carries roughly one fifth as much fisetin as the unformulated arm.
The numbers
Measured as area under the curve over twelve hours, plasma fisetin was 26.9-fold greater with FF-20 than with unformulated fisetin: an AUC of 341.4 against 12.67 [1]. Peak plasma concentration told the same story. Cmax was 238.2 ng/mL with FF-20 against 9.97 ng/mL with unformulated fisetin, more than twenty-three times higher.
Put those two facts side by side. The arm carrying about one fifth the fisetin produced roughly twenty-seven times the plasma exposure. On a per-milligram basis the difference is larger still, though the study was not designed to report it that way and it should not be presented as a formal finding.
The formulation also reduced how much fisetin was converted to geraldol. That is a mechanistic detail rather than a benefit claim, since the relative activity of fisetin and geraldol in humans is not established. No adverse events were reported during the study.
Why unformulated fisetin performs this poorly
Fisetin is a poorly water-soluble flavonoid, and the study authors open by naming its poor bioavailability when ingested as the main limit on its clinical use [1]. Taken as a raw powder or a simple capsule, much of an oral dose never reaches systemic circulation in its original form. A Cmax of 9.97 ng/mL from a gram of material is a direct measurement of that problem rather than an inference from cell studies.
This is the practical reason the gap between preclinical work and human results is so wide for this compound. Concentrations that clear senescent cells in a dish are set by the experimenter. Concentrations in a person are set by absorption, and the first human measurement of that says the ceiling is low unless something is done about delivery.
What this does and does not tell you about dosing
It tells you that milligrams on a label are not a measure of exposure, and that two products with identical label doses can differ enormously in what they deliver. If you are comparing fisetin products on price per milligram alone, this study is the reason that comparison can mislead, which is also the caveat behind our cost-per-dose analysis.
It does not tell you that FF-20 is the right product, or that higher plasma fisetin produces better outcomes. Nobody has shown that a particular plasma level of fisetin causes a clinical benefit in humans. Exposure is a necessary condition for an effect, not evidence of one.
It also does not settle dose. Note how far apart the human trials sit. One registered protocol gives 100 mg once daily for seven weeks to adults aged 50 and over [2]. The TROFFi trial in breast cancer survivors gives 20 mg/kg/day on days 1 to 3 of a fourteen-day cycle [3], which for a 70 kg participant is about 1,400 mg per day. The trial that produced actual results in patients used 100 mg daily for seven weeks [4]. These are not variations on a theme. They are different strategies, and the field has not chosen between them.
How to use this when comparing products
Treat the label dose as a starting question rather than an answer. A useful product page tells you what form the fisetin is in and whether any delivery technology is involved. If it does not, the label number is the only thing you have, and this study is a reason to discount it.
Be equally sceptical of formulation claims that cite this study loosely. The 26.9-fold figure belongs to one specific hydrogel formulation tested in fifteen people at a single dose. It is not a general property of anything described as enhanced, liposomal or bioavailable, and a product borrowing the number without having been tested is making a claim the data does not support.
Finally, hold the size of this study in mind. Fifteen healthy volunteers, one dose, twelve hours of sampling. It is the best human pharmacokinetic evidence available for fisetin, and it is still a small early study. For the formulation side of the argument, see why oral fisetin absorbs so poorly, whether liposomal and phytosomal versions justify their price, and what the evidence says about taking it with a fatty meal.
Common questions
How much fisetin actually reaches the bloodstream from a normal capsule?
In the only human pharmacokinetic study to date, 1,000 mg of unformulated fisetin produced a peak plasma concentration of 9.97 ng/mL and a twelve-hour AUC of 12.67 [1]. That is very low for a gram of ingested material, and it is a direct measurement rather than an estimate.
Does a formulated fisetin product work better?
It delivers more fisetin to plasma. In the same study a hydrogel formulation carrying 192 mg of fisetin produced 26.9 times the AUC of 1,000 mg unformulated [1]. Whether higher plasma fisetin produces better health outcomes has not been shown in any human trial.
Why do fisetin protocols use such large doses?
Largely because absorption is poor, so protocols compensate with quantity. The human trials have not converged on a dose: one protocol uses 100 mg daily [2] while the TROFFi trial uses 20 mg/kg/day in short pulses [3], roughly a fourteen-fold difference in daily intake.
Was the pharmacokinetic study safe?
No adverse events were reported during the study [1]. That is reassuring but limited: fifteen people took a single dose and were followed for twelve hours, which cannot detect anything that develops with repeated use.
Is geraldol important?
Geraldol is an active metabolite of fisetin, and the formulation tested reduced conversion to it [1]. Because the relative activity of fisetin and geraldol in humans is not established, this is best read as a mechanistic observation rather than an advantage or a drawback.
Can I use these numbers to compare two supplements?
Only if both have been tested. The measured difference belongs to one specific formulation studied in one trial. A product that has not undergone pharmacokinetic testing cannot borrow the result, whatever its marketing says.
References
- Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J Nutr Sci (2022). PMID 36304817
- Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial. Basic Clin Pharmacol Toxicol (2026). PMID 42633989
- A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design. Ther Adv Med Oncol (2026). PMID 41835341
- Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients. Food Funct (2018). PMID 29541713
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.